Erasca Stock News

Shares of Erasca Inc (NASDAQ:ERAS) saw an uptick in trading volume on Monday . 22,059 shares traded hands during trading, a decline of 94% from the previous sessions volume of 368,640 shares.The stock last traded at $15.34 and had previously closed at $16.46. A number of research firms have recently weighed in on ERAS. Bank []

Erasca Inc (NASDAQ:ERAS)’s stock price dropped 8.6% during mid-day trading on Tuesday . The company traded as low as $15.40 and last traded at $15.46. Approximately 7,247 shares changed hands during mid-day trading, a decline of 98% from the average daily volume of 367,390 shares. The stock had previously closed at $16.92. ERAS has been […]

Zacks Investment Research cut shares of Erasca (NASDAQ:ERAS) from a hold rating to a sell rating in a report published on Friday, Zacks.com reports. According to Zacks, Erasca Inc. is a clinical-stage precision oncology company singularly focused on discovering, developing and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Erasca Inc. is based in SAN []

Erasca (NASDAQ:ERAS) was downgraded by Zacks Investment Research from a hold rating to a sell rating in a research note issued to investors on Friday, Zacks.com reports. According to Zacks, Erasca Inc. is a clinical-stage precision oncology company singularly focused on discovering, developing and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Erasca Inc. is []

SAN DIEGO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Evercore ISI 4th Annual HealthCONx Conference. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer, will represent Erasca in a Fireside Chat beginning at 3:05 PM Eastern Time on Thursday, December 2, 2021. The company will also participate in one-on-one investor meetings.

SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for

Erasca (ERAS) signs an agreement with Pfizer for a clinical study, which will evaluate ERAS-007 in combination with encorafenib and cetuximab for BRAF V600E-mutant metastatic colorectal cancer.

ERAS-007, a potential best-in-class ERK1/2 inhibitor, is believed to have broad therapeutic applicability across a wide range of tumor types and indications ERAS-007, a potential best-in-class ERK1/2

SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for p

The group is diverse—a fintech, three biotechs, a real-estate investment manager, a bioscience company, and a pharmaceutical glassmaker.

SAN DIEGO, July 15, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for p